Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
9 Total results for product and free and sample content found
Scrip
20 Oct 2022
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
TrialScope Disclose
13 May 2022
Clinical trial disclosure experts Francine Lane and Thomas Wicks provide an overview of EU CTR/CTIS regulations and timelines for compliance.
Topic Market Intelligence
Scrip
26 Mar 2021
Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.
Topic Business Strategies China Company Analysis Drug Development Landscape Market Intelligence
Medtech Insight
By Reed Miller 08 Dec 2020
The $800m sale of BTG Specialty Pharmaceuticals business to SERB leaves Boston Scientific with BTG’s successful interventional oncology and vascular products.
Topic M A Market Intelligence
HBW Insight
27 Nov 2020
Infographic: COVID-19 delivers an 8% sales growth injection to Germany's supplements market in the first half of the year, accelerating a long-term expansion.
27 Nov 2020
To reach today’s Pharma decision makers, you must provide the right high-quality content to help them make educated purchasing decisions – and become loyal customers.
Topic Market Intelligence
Scrip
16 Jul 2020
The annual “Scrip Asia 100”, the highly anticipated financial performance ranking of pharma companies headquartered in the APAC region, is coming soon. Don’t miss your opportunity to position yourself as a leader in APAC pharma with a sponsorship in this indispensable publication.
Scrip
By Daniel Chancellor 27 Jan 2020
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.
In Vivo
By Ashley Yeo 11 Dec 2019
For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
Topic Market Intelligence Outlook
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
